Home About us Therapeutic Areas Sarcopenia Literature Neuropathic Pain Literature Pipeline Investors Careers News Contact Neuropathic pain (NP) represents an important Unmet Medical Need. The available treatments, in fact, are at best moderately effective or endowed with significant side effects, with the consequence of poor compliance and of unsatisfactory benefits. Adverse Events limit their use particularly in the elderly population, the fastest growing patients sector. Specifically, no drugs are currently available to satisfactorily treat NP induced by chemotherapic (CIPN) or antiviral agents. A recent Phase III trial, indeed, failed to demonstrate benefits of gabapentin for symptomatic treatment of CIPN. Glutamate is the main mediator of excitation in the Nervous System (NS). An overdrive of the glutamatergic systems has been implicated in a wide variety of NS pathologies including epilepsy, stroke, pain, trauma and neurodegenerative disorders. Overdrive of one of the glutamate receptors, the NMDA-receptor (NMDAR) plays a major pathogenic role in all the above conditions. The extreme consequences of such overdrive are seen in excitotoxicity when through accumulation of intracellular calcium neuronal death ensues. Most unselective NMDAR antagonists developed in the past to treat these disorders failed in clinical trials because of unacceptable side effects (e.g. hallucinations, psychosis, memory and motor deficits). Recently, however, Neurotune has identified BND-11624 and BND-13317 as representative compounds of a novel class of subtype-selective NMDAR antagonists which may have a much improved side effect profile compared with broad-spectrum antagonists. Recently, however, Neurotune has identified NT-11624 and NT-13317 as representative compounds of a novel class of subtype-selective NMDAR function modulators that have a much improved preclinical side effect profile compared with broad-spectrum antagonists. NT-11624 has shown a very broad spectrum of efficacy in animal models of pain with outstanding superiority in respect to standard antineuropathic agents in the antiviral induced neuropathy in rodents. Interestingly even high doses do not affect cognition and alertness. NT-11624 is currently completing clinical phase I and will move into phase II first for antiviral induced neuropathic pain in HIV patients. NT-13317 has demonstrated also outstanding efficacy in a series of rodent models of anticancer induced neuropathic pain and is close to complete the preclinical requirements for moving into phase I clinical trials. Based on its preclinical profile the first indication to be explored shall be in cancer patients undergoing chemotherapy and suffering from iatrogenic neuropathic pain. © Copyright by Neurotune Switzerland